Funding for this research was provided by:
Regione Campania (CUP H64I20000300002)
Received: 12 February 2021
Accepted: 20 February 2021
First Online: 2 March 2021
Ethics approval and consent to participate
: The study gained full approval from the Ethical Committee of the Istituto Nazionale Tumori IRCCS–Fondazione “G Pascale”. All patients have provided written informed consent to participate in the study prior to being screened.
: Not applicable.
: PAA reports grants and personal fees from BMS, Roche-Genentech, Array; personal fees from MSD, Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, NewLink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar and Boehringer-Ingelheim, all outside the submitted work. The other authors declare that they have no competing interests.